A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
OverweightObesity
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (20)

30291

Rophe Adult and Pediatric Medicine/SKYCRNG, Union City

32765

Oviedo Medical Research, Oviedo

33165

New Horizon Research Center, Miami

35124

Cahaba Research - Pelham, Pelham

37397

WR-Clinsearch, LLC, Chattanooga

39069

Prime Health and Wellness/SKYCRNG, Fayette

40213

L-MARC Research Center, Louisville

46324

Asha Clinical Research - Munster, Hammond

50265

Iowa Diabetes and Endocrinology Research Center, West Des Moines

73069

Alliance for Multispecialty Research, LLC, Norman

75149

Southern Endocrinology Associates, Mesquite

75230

Velocity Clinical Research, Dallas, Dallas

77401

The University of Texas Health Science Center at Houston, Bellaire

78229

Pinnacle Clinical Research, San Antonio

78231

Consano Clinical Research, LLC, Shavano Park

83404

Rocky Mountain Clinical Research, Idaho Falls

90057

Velocity Clinical Research, Westlake, Los Angeles

91978

Encompass Clinical Research, Spring Valley

92701

Southern California Dermatology, Inc., Santa Ana

96814

East-West Medical Research Institute, Honolulu

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06047548 - A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Biotech Hunter | Biotech Hunter